Objective The purpose of the present study was to evaluate the impact of ex vivo T cell depleted (TCD) by CD34+ selection on the incidence and severity of oropharyngeal mucositis (OM) after myeloablative allogeneic stem cell transplant (allo-SCT) with total body irradiation (TBI) conditioning. This approach has the advantage of avoiding methotrexate for graft versus host disease (GVHD) prophylaxis. Patients and Methods We analyzed the incidence and severity of OM in a cohort of 105 consecutive patients who underwent CD34+ selected (peripheral blood stem cells (PBSCs) from human leukocyte antigen (HLA)-identical siblings) allo-SCT with total body irradiation (TBI) conditioning. OM was graded by the World Health organization (WHO) and the Bearman regimen-related toxicity (RRT) scales. Results The incidence of WHO grade 3-4 OM was 34.3 %. There were no cases of grade 3-4 OM by the RRT scale. Significant correlation was found between the severity of OM and the use of intravenous (IV) narcotic medications (r 2 =0.15, p=0.004), total parenteral nutrition (TPN; r 2 = 0.68, p<0.001), and hospital length of stay (LOS) (r 2 =0.12, p=0.01).
Introduction
Oropharyngeal mucositis (OM) is a serious complication that develops in the majority of patients undergoing myeloablative conditioning for allogeneic hematopoietic stem cell transplant (allo-SCT) leading to significant morbidity and prolonged hospitalizations [1] . OM is considered to be the single worst complication of myeloablative conditioning in patientreported outcomes [2] . Presenting as oral lesions with severe pain, with dysphagia/odynophagia, and with increased risk of infections from mucosal erosions, OM significantly impacts patient quality of life in the early transplant period. The major risk factors associated with development of OM include myeloablative conditioning, radiotherapy, and use of methotrexate for GVHD prophylaxis [3] . Severe OM, as defined by Ankit Anand and Prathima Anandi contributed equally to this work.
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World Health Organization (WHO) criteria, occurs in up to 75 % of patients undergoing allo-SCT with myeloablative conditioning regimens [4] . The manifestations of OM severity range from mild oral erythema to severe oral ulcerations requiring intravenous infusion of narcotic analgesics, parenteral nutrition, and possibly preventative intubation for airway protection [5] . Denudation of mucosal lining may also contribute to bacteremia and potentially delay recovery and hospital discharge [6, 7] . To date, palifermin, a human recombinant keratinocyte growth factor, is the only agent approved by US Food and Drug Administration (FDA) for prevention of OM in myeloablative transplantation. However, palifermin is associated with significant additional costs in the peritransplant period [8] .
The incidence of WHO grade 3-4 OM after total body irradiation (TBI)-based myeloablative conditioning has been reported to exceed 50 % when methotrexate is used for graft versus host disease (GVHD) prophylaxis [4, 9] . Methotrexate functions as an antimetabolite and antiproliferative agent, interrupting a variety of interactions involving endothelium, extracellular matrix, metalloproteinases, submucosal reactions, and connective tissue [10] . The risk of mucositis induced by methotrexate may be further increased if the patient carries methyltetrahydrofolate reductase (MTHFR) 677 T allele [11] . Substitution of methotrexate by alternative agents such as mycophenolate or sirolimus significantly reduces the severity of OM [4, 12, 13] .
Immunomagnetic CD34+ selection of the graft, a method of ex vivo T cell depletion (TCD), is a highly effective strategy for reducing GVHD. The Miltenyi CliniMACS system for CD34+ selection is currently FDA-approved. Initial reports of CD34+ selection allo-SCT have focused on the benefits of reducing acute or chronic GVHD and improving GVHD-free survival [14] [15] [16] [17] . By avoiding the administration of methotrexate, CD34+ selection could theoretically reduce the risk of OM. Goldberg et al. have studied the impact of palifermin in reducing mucositis in a cohort of 251 patients, but only 11 had TCD with the Miltenyi CliniMACS system [18] . We conducted a single institution retrospective analysis of the severity and incidence of OM and its related outcomes in 105 consecutive recipients of TBI-based myeloablative CD34+-selected allo-SCT.
Patients and methods

Study design
This is a single institute retrospective study of 105 consecutive patients with hematologic malignancies undergoing myeloablative T cell depleted (TCD) hematopoietic cell transplant (HCT), from a 6/6 human leukocyte antigen (HLA)-identical sibling at the Hematology Branch of the National Heart, Lung and Blood Institute at the National Institutes of Health between 2006 and 2014 on institutional review board-approved protocols (06-H-0248, 07-H-0136, 12-H-0028, 13-H0144). The trials were registered at www.clinicaltrials.gov [NCT00378534, NCT00467961, NCT01517035, NCT01866839]. Written informed consent, consistent with the Helsinki Declaration, was obtained from all patients and donors.
Transplantation protocols
All subjects received a full myeloablative conditioning regimen consisting of fludarabine (25 mg/m 2 /day) from day −8 to day −4 and age-adapted fractionated TBI from day −7 to day −4, followed by cyclophosphamide (60 mg/kg/day) on day −3 and day −2. TBI was delivered in eight fractions at a total dose of 1200 cGy with lung shielding to 600 cGy for subjects aged <55 years and 400-600 cGy for subjects aged ≥55 years (21 % of subjects). None of the subjects received palifermin or intravenous methotrexate. On day 0, subjects received a granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood stem cell product selected for CD34+ progenitors using the Miltenyi CliniMACS Plus system (Miltenyi Biotec Inc., Cambridge, MA) along with a planned T lymphocyte dose ranging between 5 and 50× 10 4 CD3+/kg (resulting in a 3-4 log TCD graft). Low-dose cyclosporine was administered until day 21. Low-dose cyclosporine from day −6 to day +21 was used for GVHD prophylaxis. Supportive care did not change in this period. Regular oral hygiene was performed with mouthwashes, which did not change in the period of observation. Prophylaxis with systemic antibiotics for prevention of bacterial infection is not employed at our center.
Outcome endpoints
OM was graded from the start of transplant conditioning (day −8) until day +21. The peak grades of OM by WHO grading [19] and by the Bearman RRT scale [20] were recorded. Esophagitis was not scored for this study. The total duration of IV narcotic analgesia in days, duration of total TPN in days, and microbiologic data were also collected through the same period.
Statistical analysis
Summary statistics such as sample proportions, medians, standard deviations, and 95 % confidence intervals were used to describe patient characteristics. Unpaired t tests were used to compare groups. Statistical significance was considered when p<0.05. All statistical analyses were performed using Prism 5.03 (GraphPad Software, Inc., La Jolla, CA)
Results
Patient characteristics
The median age was 42 years. Seventy-eight percent received full ablative transplants (1200 cGy) while 22 % received reduced intensity (400-600 cGy) TBI. Patient and transplant characteristics are summarized in Table 1 . Differences between transplant protocols are summarized in Supplementary Table S1 . The median time to absolute neutrophil count recovery to >500/μL was 12 days.
OM incidence and severity
WHO grade 2-4 was observed in 46.7 % of subjects and WHO grade 3-4 in 34.3 % of subjects. Bearman grade 1 was observed in 53.3 %, grade 2 in 15.2 %, and grade 3-4 in 0 %. Grading of OM by the WHO and Bearman scales were highly correlated (r 2 =0.48, p<0.0001) (Fig. 1) . (Fig. 2) but not with the occurrence of bacteremia.
Role of conditioning intensity
Subjects who received reduced intensity conditioning had significantly lower incidence and severity of mucositis (Fig. 3 ) and associated outcomes ( Table 2 ). Only one subject receiving 400-600 cGy TBI had WHO grade ≥3 OM and none had grade ≥2 Bearman.
Discussion
We show that OM remains a problem in TBI-based myeloablative stem cell transplantation and is correlated with IV narcotic requirements, duration of TPN, and prolonged hospital LOS. With CD34+ selection and 1200 cGy (fully ablative) TBI-based conditioning, the peak incidence of WHO grade 3-4 OM was 43 %, but Bearman grade 3-4 OM was 0 %, while the severity was even lower with reduced intensity conditioning.
While ours was an uncontrolled study, the rates of OM with CD34+ selection in our study compare favorably with TBIbased transplant regimens containing methotrexate [9, 4] . The incidence of WHO grade 2-4 OM was 46.7 % which is lower than in the study by Langner et al. that reported WHO grade 2-4 OM incidence ranging from 60 to 86 % in subjects who received or did not receive palifermin, respectively [9] . Incidence of WHO grade 3-4 OM in the same study ranged from 37 to 53 %, in subjects who received or did not receive palifermin, respectively. In a prospective study with a different OM grading system, Cutler et al., using full-dose TBI at 1400 cGy, reported an incidence of moderate-severe OM of 92 % in methotrexate arm as opposed to 64 % in the nonmethotrexate arm [4] . Reductions in OM by substituting methotrexate have recently been confirmed by a multicenter randomized trial of tacrolimus/sirolimus versus tacrolimus/methotrexate. Tacrolimus/sirolimus did not impact GVHD-free survival but OM was greatly reduced [13] , Taken together, these data suggest that avoidance of methotrexate by CD34+ selection is at least moderately effective in reducing the peak severity of OM.
It is notable that in our study, subjects did not receive palfermin, which is an N terminal truncated (ΔN23KGF) version of recombinant human KGF-1, and currently the only FDA-approved agent for treatment of OM [21, 1] . Palifermin was first demonstrated to be efficacious for treatment of OM in the setting of autologous SCT with TBI-based conditioning regimens. Since its first approval by FDA in 2004, studies have shown its efficacy in reducing the severity, the incidence, and the duration of OM grades 2-4, in the allogeneic transplant setting as well. However, its efficacy in non-TBI-based myeloablative conditioning is controversial [1, 9, 22] . Palifermin does not offer a survival benefit and does not impact the incidence of acute or chronic GVHD. Another major drawback with the use of palifermin is the cost associated with its use. Nooka et al. reported additional costs of $5511 for Fig. 3 Oropharyngeal mucositis severity based upon conditioning intensity myeloma and $13,792 for lymphoma patients for preventing 1 day of patient controlled analgesia [8] . Others have justified palifermin as being cost-neutral [23] . Palifermin use has been described in allo-HSCT [9, 24] . Goldberg et al. showed that palifermin significantly decreased the durations of TPN, patient-controlled analgesia (PCA), and hospital LOS in patients who received a myeloablative TBI-based but not busulfan-based chemotherapy conditioning in TCD allo-SCT recipients [18] . This is so far the largest published experience with palifermin in allo-SCT and suggests that palifermin may offer incremental benefit even in TCD transplantation.
Our study also described the practical consequences related to OM severity such as narcotic or TPN utilization and hospital LOS. The mean duration of intermittent narcotic analgesia was 7.1 days (range 0-21 days), and 62 patients (59.1 %) required intermittent narcotic analgesia. These results are comparable to a prospective randomized trial by Bolwell et al. who reported that 94 % of patients in the methotrexate arm received narcotic analgesics for an average of 15.5 days and 75 % of patients in the methotrexate-free arm received narcotic analgesics with an average of 9.5 days [12] . Another prospective randomized study by Langner et al. reported average narcotic analgesia duration of 7 days [9] . Thirty-six patients (34.3 %) required TPN support in our study. These results are somewhat different from the randomized trial by Bolwell et al. that reported TPN use by 19 % of patients in the methotrexate-free arm and TPN use by 64 % of patients in the methotrexate arm. The difference in results may be explained by the small sample size in that study with 21 patients and 19 patients in each arm respectively [12] . In contrast to a retrospective study by Robien et al., we did not find any correlation between body mass index (BMI) and degree of mucositis.
Robien et al. had used methotrexate (15 mg/m
2 ) for GVHD prophylaxis, and the correlation with mucositis was thought to be due to increasing dose of chemotherapeutic agents with increasing BMI [25] .
In this retrospective analysis, we have ascertained the severity of OM and related complications in CD34+ selected TBI-based transplants. This is the largest study addressing OM in TBI-based CD34+ selected transplants. Patients were uniformly treated; these were all HLA-identical sibling transplants, and palifermin was not used. However, the study is limited by being a retrospective chart review at a single center without a control arm. While not ideal, retrospective review does permit the identification of the peak grade of mucositis. In the WHO scale, the extent of functional limitation (ability to swallow solids (grade 2), liquids but not solids (grade 3), and neither solids nor liquids (grade 4)) is easily discernible from nutritionist charting. Also, the Bearman RRT scale allows distinctive differentiation between grade 1 (no IV pain medication) and grade 2 (IV narcotics) and grade 3 (intubation for airway protection). For instance, one of our CD34+ selected patients required intubation for airway protection. More accurate assessments of OM, particularly related to the kinetics and duration, certainly require regular prospective monitoring by trained observers. Prospective monitoring also offers the opportunity to examine not only the peak but also the duration of OM, exemplified by the Clinical Trials Network (CTN) study reported by Cutler et al. [13] .
Genetic and metabolic determinants of the risk of mucositis after intense chemo-radiation are being discovered and could help stratify patient risk. Most polymorphisms identified so far focus on the folate/methotrexate pathway [26] [27] [28] 11] , but the cytochrome p450 pathway [29] has also been found OM oral mucositis, ANC absolute neutrophil count, TPN total parenteral nutrition, LOS length of stay in the hospital significantly involved in the risk of OM. Understanding the impact of polymorphisms could impact not only risk stratification but also treatment strategies [30] . We did not test for genetic polymorphisms in our cohort of patients.
In conclusion, this study has shown that CD34+ selection in the setting of a TBI-conditioned allogeneic transplant is associated with tolerable rates of oropharyngeal mucositis. The risk and severity of OM deserve study as an important secondary endpoint in planned randomized studies of Miltenyi CD34+ selection.
